BACKGROUND: The Occluded Artery Trial (OAT) showed no difference in outcomes between percutaneous coronary intervention (PCI) versus optimal medical therapy (MED) in patients with persistent total occlusion of the infarct-related artery 3 to 28 days post-myocardial infarction. Whether PCI may benefit a subset of patients with preservation of infarct zone (IZ) viability is unknown. METHODS AND RESULTS: The OAT nuclear ancillary study hypothesized that (1) IZ viability influences left ventricular (LV) remodeling and that (2) PCI as compared with MED attenuates adverse remodeling in post-myocardial infarction patients with preserved viability. Enrolled were 124 OAT patients who underwent restingnitroglycerin-enhanced technetium-99m sestamibi single-photon emissioncomputed tomography (SPECT) before OAT randomization, with repeat imaging at 1 year. All images were quantitatively analyzed for infarct size, IZ viability, LV volumes, and function in a core laboratory. At baseline, mean infarct size was 26% ± 18 of the LV, mean IZ viability was 43% ± 8 of peak uptake, and most patients (70%) had at least moderately retained IZ viability. There were no significant differences in 1-year end-diastolic or end-systolic volume change between those with severely reduced versus moderately retained IZ viability, or when compared by treatment assignment PCI versus MED. In multivariable models, increasing baseline viability independently predicted improvement in ejection fraction (P = .005). There was no interaction between IZ viability and treatment assignment for any measure of LV remodeling. CONCLUSIONS: In the contemporary era of MED, PCI of the infarct-related artery compared with MED alone does not impact LV remodeling irrespective of IZ viability.
RCT Entities:
BACKGROUND: The Occluded Artery Trial (OAT) showed no difference in outcomes between percutaneous coronary intervention (PCI) versus optimal medical therapy (MED) in patients with persistent total occlusion of the infarct-related artery 3 to 28 days post-myocardial infarction. Whether PCI may benefit a subset of patients with preservation of infarct zone (IZ) viability is unknown. METHODS AND RESULTS: The OAT nuclear ancillary study hypothesized that (1) IZ viability influences left ventricular (LV) remodeling and that (2) PCI as compared with MED attenuates adverse remodeling in post-myocardial infarctionpatients with preserved viability. Enrolled were 124 OATpatients who underwent resting nitroglycerin-enhanced technetium-99m sestamibi single-photon emission computed tomography (SPECT) before OAT randomization, with repeat imaging at 1 year. All images were quantitatively analyzed for infarct size, IZ viability, LV volumes, and function in a core laboratory. At baseline, mean infarct size was 26% ± 18 of the LV, mean IZ viability was 43% ± 8 of peak uptake, and most patients (70%) had at least moderately retained IZ viability. There were no significant differences in 1-year end-diastolic or end-systolic volume change between those with severely reduced versus moderately retained IZ viability, or when compared by treatment assignment PCI versus MED. In multivariable models, increasing baseline viability independently predicted improvement in ejection fraction (P = .005). There was no interaction between IZ viability and treatment assignment for any measure of LV remodeling. CONCLUSIONS: In the contemporary era of MED, PCI of the infarct-related artery compared with MED alone does not impact LV remodeling irrespective of IZ viability.
Authors: L Bolognese; G Cerisano; P Buonamici; A Santini; G M Santoro; D Antoniucci; P F Fazzini Journal: Circulation Date: 1997-11-18 Impact factor: 29.690
Authors: G Germano; H Kiat; P B Kavanagh; M Moriel; M Mazzanti; H T Su; K F Van Train; D S Berman Journal: J Nucl Med Date: 1995-11 Impact factor: 10.057
Authors: Nicos Spyrou; Stuart D Rosen; Farzin Fath-Ordoubadi; Rohan Jagathesan; Rodney Foale; Jaspal S Kooner; Paolo G Camici Journal: J Am Coll Cardiol Date: 2002-10-02 Impact factor: 24.094
Authors: J E Udelson; P S Coleman; J Metherall; N G Pandian; A R Gomez; J L Griffith; N L Shea; E Oates; M A Konstam Journal: Circulation Date: 1994-06 Impact factor: 29.690
Authors: Harmony R Reynolds; Sandra A Forman; Jacqueline E Tamis-Holland; Philippe Gabriel Steg; Daniel B Mark; Camille A Pearte; Antonio C Carvalho; George Sopko; Li Liu; Gervasio A Lamas; Mariusz Kruk; Krystyna Loboz-Grudzien; Witold Ruzyllo; Judith S Hochman Journal: Am Heart J Date: 2012-03 Impact factor: 4.749
Authors: Rahul R Jhaveri; Harmony R Reynolds; Stuart D Katz; Raban Jeger; Elzbieta Zinka; Sandra A Forman; Gervasio A Lamas; Judith S Hochman Journal: J Card Fail Date: 2012-11 Impact factor: 5.712
Authors: Harvey D White; Harmony R Reynolds; Antonio C Carvalho; Camille A Pearte; Li Liu; C Edwin Martin; Genell L Knatterud; Vladimír Džavík; Mariusz Kruk; Philippe Gabriel Steg; Warren J Cantor; Venu Menon; Gervasio A Lamas; Judith S Hochman Journal: Am Heart J Date: 2012-04 Impact factor: 4.749
Authors: Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas Journal: Circulation Date: 2011-10-24 Impact factor: 29.690
Authors: Vinod Jorapur; Terje K Steigen; Christopher E Buller; Vladimír Dzavík; John G Webb; Bradley H Strauss; Eunice E S Yeoh; Peter Kurray; Leszek Sokalski; Mauricio C Machado; Shari S Kronsberg; Gervasio A Lamas; Judith S Hochman; G B John Mancini Journal: Catheter Cardiovasc Interv Date: 2008-11-15 Impact factor: 2.692
Authors: Christopher Adlbrecht; Kurt Huber; Harmony R Reynolds; Antonio C Carvalho; Vladimír Džavík; Philippe Gabriel Steg; Li Liu; Paolo Marino; Camille A Pearte; James M Rankin; Harvey D White; Gervasio A Lamas; Judith S Hochman Journal: Int J Cardiol Date: 2014-03-28 Impact factor: 4.164